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In Europe colorectal cancer (CRC) is the second most common cause of cancer related death 29 
in both men and women.(1) The 5-year survival is strongly dependent on disease stage and 30 
rapidly decreases in individuals with lymph node or distant metastasis. Current guidelines for 31 
high-risk stage II and stage III patients, advice adjuvant fluoropyrimidine-based 32 
chemotherapy with addition of oxaliplatin as standard therapy. This combination has shown 33 
to significantly improve disease-free survival (DFS) and overall survival (OS).(2, 3) 34 
Adjuvant therapy with bevacizumab, a humanized anti-VEGF monoclonal antibody, has only 35 
demonstrated to improve outcome in patients with metastatic stage IV disease and is 36 
therefore currently not recommended in other stages. (3-8) However, due to heterogeneity of 37 
colon cancer, one could argue that some subpopulations could possibly benefit from targeted 38 
therapy in an adjuvant setting. To identify such potential groups, predictive parameters are 39 
necessary. Currently most biomarkers focus on tumour cells. However, recently the “seed-40 
and-soil” principle has been revisited, focusing on the tumour –microenvironment as a major 41 
factor responsible for metastasis.(9, 10)  Studies have shown that during cancer progression, 42 
the normal stromal host compartments transform, due to complex intercellular 43 
communication between surrounding stromal host cells and cancer cells, in which a cross-talk 44 
of signalling molecules between these compartments, leads to an activated state with 45 
production of various cytokines and growth factors creating an area favouring cancer  46 
progression and invasion. Thus, illustrating the importance of intratumoural stroma. (11-14) 47 
Consistent with this principle, it has been proven that in colon cancer, high amounts of 48 
intratumoural stroma are associated with poor survival compared to tumours with low 49 
amounts of stroma. (15-18) This prognostic parameter is also known as the tumour-stroma 50 
ratio (TSR), and entails a simple microscopic quantification of the amount of intratumoural 51 
stroma on a tumour tissue slide, which is derived after surgical resection. It has been 52 
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validated in multiple studies, thereby demonstrating the robustness and potential of this fairly 53 
simple, quick and cost effective pathological technique. (15, 17, 18) 54 
Since the prognostic quality of the TSR is clear, it is interesting to evaluate whether this 55 
parameter could also serve as a predictive marker to improve risk stratification of patients 56 
with high-risk stage II and III colon cancer, in order to determine if subpopulations  57 
could benefit from the VEGF antibody bevacizumab in an adjuvant setting. Our hypothesis 58 
was that patients with high stromal tumours would benefit from adjuvant bevacizumab, 59 
considering these tumours hold features promoting cancer progression and metastasis, hence 60 
possessing  a more aggressive phenotype. (11, 12, 14) 61 
To study this concept, we used the study population from the AVANT trial (BO17920), a 62 
prospective randomized trial studying the addition of bevacizumab to oxaliplatin-based 63 
chemotherapy in an adjuvant setting. This was a negative study, showing no prolongation of 64 
DFS and for OS even suggesting a potential detrimental effect when adding bevacizumab to 65 
the chemotherapy regime. We considered that if the TSR is able to identify patients that do 66 
benefit from bevacizumab in an adjuvant setting, it could serve as a selection tool to optimize 67 
adjuvant treatment outcomes in colon cancer.  68 
Therefore, the aim of this study was to investigate the predictive potential of TSR, by 69 
determining the effects on DFS and OS in patients with high-risk stage II and stage III colon 70 
cancer who received standard oxaliplatin-based chemotherapy with or without addition of 71 
bevacizumab.  72 
 73 
Patients and Methods 74 
Study design  75 
Available Haematoxylin and Eosin (H&E) stained tumour slides from patients randomized in 76 
the AVANT trial were included in our analysis. Patients entering the AVANT trial had 77 
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undergone potential curative treatment, including surgery (before randomization) followed by 78 
adjuvant chemotherapy.  79 
Inclusion criteria were histologically confirmed high-risk stage II or stage III colon 80 
carcinoma. The study had an open label design, in which patients were randomly assigned 81 
1:1:1 to one of the three treatment regimens; FOLFOX-4 for 24 weeks followed by 82 
observation for 24 weeks, bevacizumab–FOLFOX-4 or bevacizumab–XELOX for 24 weeks 83 
followed by bevacizumab monotherapy for 24 weeks. Patients were recruited in 330 centres 84 
in 34 countries. For detailed trial design, see de Gramont et al. (5) 85 
For our study, archival material was used in an anonymized matter, therefore no additional 86 
informed consent was needed. 87 
 88 
Histopathologic scoring  89 
The TSR was determined in all patients from whom a H&E stained formalin-fixed paraffin-90 
embedded tissue slide from the primary tumour was available.  91 
Pathological examination was performed as described by Mesker et.al 2007 (For detailed 92 
description see Appendix 1). Two investigators (SZ, GvP) scored stromal percentage in a 93 
blinded manner. Scoring percentages were given per 10-fold (10%, 20% etc.) per image field. 94 
For statistical analysis, we defined two groups; stroma-high (> 50%) and stroma-low (≤50%) 95 
as determined a priori to have maximum discriminative power (Figure S1). (17, 18)  96 
 97 
Statistical analysis 98 
Statistical analysis was performed using SPSS software version 23.0. The primary endpoint, 99 
DFS, was defined as the time between randomization and recurrence, new occurrence of 100 
colon cancer, or death from any cause.  Alive and event-free patients at the clinical cut-off 101 
date were censored at the last date at which they were known to be disease-free and/or alive.  102 
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The secondary endpoint, OS, was defined as time from randomization to death. Patients who 103 
were still alive at the clinical cut-off date were censored at the date at which they were last 104 
confirmed to be alive.  105 
Kaplan-Meier method and log rank test were used to analyse time-to-event endpoints. Intra-106 
observer variability was tested using Cohen’s kappa coefficient.  107 
Univariate and multivariable analyses were performed using Cox-regression analysis. For 108 
predictive analysis, a Cox proportional hazard model including an interaction term between 109 
treatment arms and TSR was used. The interaction test was used to test the null hypothesis 110 
that TSR is not predictive for response to bevacizumab.  111 
Parameters with a p- value less than 0.10 in the univariate analysis, were included in 112 
multivariable analyses. 113 
 114 
Results 115 
Study population  116 
In the AVANT trial, a total of 3451 patients were recruited between 2004 and 2007. We 117 
received a total of 1213 histological samples. After scoring all samples, baseline clinical 118 
patient information was used for analysis. Upon this, one patient was excluded due to the 119 
presence of stage IV disease at time of randomization.  120 
The final study population comprised 1212 patients, with respectively 405 (33.4%) patients in 121 
the FOLFOX-4 arm, 401 (33.1%) in the bevacizumab – FOLFOX-4 arm and 406 (33.5%) in 122 
the bevacizumab - XELOX arm.  123 
Patient characteristics were reasonably balanced between the different groups (Table 1). 124 
Considering our study population compromised only a selection of the total AVANT 125 
population, we compared our study population to the total AVANT population. There were 126 
no apparent differences in distribution between treatment arms, stage, gender and age. 127 
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Noteworthy to mention, in the AVANT trial high-risk stage II patients were recruited solely 128 
for exploratory analysis. Efficacy (intention-to-treat (ITT)) analysis was only performed on 129 
stage III disease.  Our study population consists of 205 (16.9%) high-risk stage II and 1007 130 
(83.1%) stage III cases, which were both used in the analysis because both groups are 131 
considered as candidates for adjuvant chemotherapy according to current European 132 
guidelines.(22)   133 
 134 
Scoring tumour stroma-ratio 135 
Of 1212 evaluated patients, 339 (28.0%) were scored as stroma-high and 824 (68.0%) as 136 
stroma-low. Forty-nine (4.0%) samples could not be scored for TSR due to poor histological 137 
quality and were therefore excluded. These samples consisted either of too little tissue 138 
material to score (i.e. biopsies), exclusively muscle tissue and/or lymph node tissue. 139 
Cohen’s kappa coefficient revealed a good level of agreement in the classification. 140 
Cox regression interaction term for TSR and treatment arms showed a significant value for 141 
DFS (p = 0.005) and OS (p=0.007) (Table S2). 142 
Disease-free survival 143 
DFS was significantly shorter in patients with stroma-high tumours compared to patients with 144 
stroma-low tumours, HR 1.75 (95% CI 1.32-2.33; p< 0.001) (Figure 1).  145 
In the total BEP study population the addition of bevacizumab did not prolong the DFS (p= 146 
0.23) compared to FOLFOX-4 monotherapy and suggests a potential detrimental effect on 147 
DFS (Figure S2). In the Cox-regression analysis, TSR had a HR of 2.92 (95% CI 1.78 – 4.79; 148 
p<0.001) for the low versus high stromal tumours. The interaction model for treatment arms 149 
and TSR, showed a significant predictive value (p = 0.005) for treatment effect in the two 150 
TSR-groups for DFS (Table S2). In the stroma-low group this effect was significant, with a 151 
HR of 1.94 (95% CI 1.24 – 3.04; p= 0.004) for bevacizumab –FOLFOX-4 versus FOLFOX-152 
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4. For bevacizumab – XELOX this was not seen, with a HR of 1.07 (95% CI 0.64 – 1.77; p= 153 
0.80). In the stroma-high tumours a trend for better DFS outcome was seen in the 154 
bevacizumab – FOLFOX-4 group versus FOLFOX-4 (HR 0.61 (95% CI 0.35-1.07; p= 0.08). 155 
For bevacizumab- XELOX versus FOLFOX-4 this was not seen (HR 0.78 (95% CI 0.47-156 
1.30; p= 0.35)) (Table S2, Figure 2). 157 
The univariate Cox regression analysis revealed TSR (p< 0.001), gender (p= 0.05), disease 158 
stage (p= 0.002) and MMR status (p= 0.04) as statistically significant prognosticators for 159 
DFS. In the multivariable analysis TSR (p= 0.003), gender (p= 0.013) and disease stage (p= 160 
0.004) maintained significance (Table S1). 161 
 162 
Overall survival 163 
As shown in Figure 1, patients with stroma-high tumours had a significant shorter OS 164 
compared to patients with stroma-low tumours (HR 1.54 (95% CI 1.04-2.29; p= 0.03)). In the 165 
total BEP study population, the addition of bevacizumab did not prolong the OS (p = 0.17) 166 
compared to FOLFOX-4 monotherapy (Figure S2). 167 
Cox-regression analysis for OS showed a HR of 3.14 (95%CI 1.57 – 6.26; p= 0.001) for TSR 168 
with regard to high versus low stromal tumours. The interaction model showed a similar 169 
pattern as for DFS, with a significant interaction term between treatment and TSR-group (p= 170 
0.007) (Table S2). Stroma-low tumours in the bevacizumab – FOLFOX-4 arm versus 171 
FOLFOX-4 arm had a significant worse OS, HR of 2.53 (95%CI 1.36-4.71; p= 0.003). For 172 
stroma-high tumours this was not significant, with a HR of 0.50 (95%CI 0.22-1.14; p= 0.10). 173 
For bevacizumab – XELOX versus FOLFOX-4 the HR was 1.13 (95% CI 0.55-2.31; p= 174 
0.74) for stroma-low tumours and HR 0.74 (95% CI 0.37-1.51; p= 0.41) for stroma-high 175 
tumours (Table S2, Figure 3). 176 
The univariate analysis for OS showed TSR (p= 0.03), gender (p= 0.006), disease stage (p= 177 
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0.04) and BRAF status (p= 0.10) as statistically significant prognosticators. In the 178 
multivariable analysis TSR (p= 0.05), gender (p= 0.002) and disease stage (p= 0.05) 179 
maintained significance (Table S1). 180 
No additional exploratory analyses were performed on patients from whom molecular 181 
variables were available (i.e. MMR status, KRAS and BRAF), due to non-significance in the 182 
Cox-regression analysis.  183 
Discussion 184 
In our study, we evaluated the predictive potential of TSR in hopes of being able to select 185 
subpopulations with high-risk stage II and III colon cancer that could benefit from adjuvant 186 
bevacizumab. Prior research failed to show benefit from addition of bevacizumab to standard 187 
chemotherapy regimens in these patients and is therefore currently only recommended in 188 
metastatic disease.(4-8, 23) Our hypothesis was that high-risk stage II and III patients with 189 
high stromal tumours would benefit from adjuvant bevacizumab, considering the pro-190 
carcinogenic features these tumours possess and association with a worse survival.(15-18, 24) 191 
In our study the TSR validated as a predictive parameter, however without clinical 192 
implications. As assumed, the stroma-low group had no benefit whatsoever from addition of 193 
bevacizumab and even showed a significantly detrimental effect on survival, most 194 
pronounced in the bevacizumab- FOLFOX-4 group. This was in accordance with the 195 
AVANT ITT- analysis and supports current guidelines which discommend adjuvant anti-196 
VEGF in stage II/III disease. It is not completely understood why this was so evident in this 197 
group and not as pronounced in the XELOX-group. Considering capecitabine is 198 
biotransformed into active metabolites that mimic 5-FU infusion, one could consider these 199 
biologically equivalent and of similarly efficacy when administrated correctly.(25) Previous 200 
studies investigating non-inferiority of  capecitabine in combination with oxaliplatin versus 201 
5-FU with oxaliplatin, correspondingly showed either similar efficacy or inconclusive results 202 
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regarding non-inferiority. (26-30) The NO16966 accordingly showed similar performance of 203 
XELOX and FOLFOX in terms of OS, when adding bevacizumab. (31) Taking this into 204 
account, it would be less likely to regard the observed results as due to an interaction of 205 
FOLFOX with bevacizumab. The AVANT ITT-analysis does show considerably less adverse 206 
events, doses reductions, -delays or interruptions in the XELOX-group compared to the other 207 
groups, suggesting less toxicity and perhaps therefore better survival outcomes (for details, 208 
see de Gramont et al).(5) However, since the ITT-analysis only entails stage III patients, 209 
these results have to be adjusted for stage before correlation to our cohort is possible.  210 
In contrast with low stromal tumours, in patients with stroma-high tumours we did observe a 211 
beneficial trend with addition of bevacizumab. Although not significant, this was an 212 
anticipated effect when regarding high stromal tumours as more aggressive due to the cross-213 
talk between their local microenvironment and tumour cells. This finding, in combination 214 
with previous research validating the TSR as an independent prognostic parameter, does 215 
suggest that there could be potential in the TSR as a predictive tool with clinical 216 
implications.(15, 17, 18) Perhaps not solely with TSR, but in combination with additional 217 
markers.(32) However, that would compromise the simplicity and costs effectiveness of the 218 
current technique, which could be easily incorporated in routine diagnostics. Currently 219 
extensive research is being performed regarding the tumour-microenvironment and response 220 
to anti-angiogenic therapy. It has become increasingly clear that stromal cells not only 221 
provide a target for cancer therapy, but also have an essential role in anti-angiogenic 222 
resistance. (33) An issue, which is already relevant to patient groups receiving these agents in 223 
routine clinical practice, since benefit on overall survival with addition of bevacizumab is 224 
often borderline significant or lacking depending on the chemotherapy regimen.(34-36) 225 
Better understanding of these mechanisms will make it possible to identify sensitive targets 226 
and/or phenotypes to overcome these tumour escape mechanisms. For instance, Smith et.al 227 
10 
 
reported two stromal phenotypes (i.e. tumour-vessel and stromal-vessel) based on CD31 and 228 
α-smooth muscle actin (α-SMA) staining. In mCRC, tumour-vessel phenotype tumours 229 
appeared to be more sensitive to combination oxaliplatin-based chemotherapy with 230 
bevacizumab compared to the stromal-vessel phenotype.(37) It would be interesting to 231 
correlate these phenotypes to the TSR, to possibly improve the predictive performance, but 232 
also to determine whether there is any prognostic relevance in metastatic disease.  233 
A possible limitation of this study is the fact we only investigated a selection of the total 234 
AVANT study population, though evenly balanced, making it possible that the study is 235 
underpowered.   236 
Nevertheless, despite the fact the findings were non-significant, we do find the potential 237 
beneficial survival trend that was observed in the stroma-high tumours with addition of 238 
bevacizumab, is worthwhile for further investigation with or without additional markers. 239 
Since this is one of the first studies evaluating this principle, we feel that we should not 240 
abandon this principle right away and validation of the findings would be necessary, to 241 
definitely rule out a coincidental finding. Considering very limited new targeted therapies 242 
have come available for treatment of colorectal cancer after the introduction of bevacizumab 243 
over a decade ago, maximum efficient utilization of this drug would be desirable. 244 
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Titles and legends to figures 413 
Figure 1. Kaplan-Meier survival curves of DFS (A) and OS (B) of stroma-low versus 414 
stroma-high in the total patient population [DFS HR 1.75 (95% CI 1.32-2.33; p< 415 
0.001)│OS HR 1.54 (95% CI 1.04-2.29; p= 0.03)] 416 
― Tumour stroma-low 417 
― Tumour stroma-high 418 
Figure 2.Disease-free survival: (A) Stroma-low, (B) Stroma-high 419 
― 1: FOLFOX-4 420 
― 2: FOLFOX-4 + bevacizumab 421 
― 3: XELOX + bevacizumab 422 
Figure 3. Overall survival: (A) Stroma-low, (B) Stroma-high 423 
― 1: FOLFOX-4 424 
― 2: FOLFOX-4 + bevacizumab 425 
― 3: XELOX + bevacizumab 426 
Table 1. Patient characteristics 
  
Total study 
population Tumour - stroma ratio   
  stroma -low stroma-high   
N (%) N = (%) N = (%) p- value
Treatment FOLFOX-4 405 (33,4%) 267 68% 123 32% 0.32
FOLFOX-4 
+bevacizumab 401 (33,1%) 284 73% 103 27%   
XELOX   
+bevacizumab 406 (33,5%) 273 71% 113 29%   
Gender Male 673 (55,5%) 453 70% 195 30% 0.43 
Female 539 (44,5%) 371 72% 144 28%   
Age (years) <= 50 278 (22,9%) 189 72% 72 28% 0.75 
51 - 64 556 (45.9%) 379 71% 152 29%   
65 - 70 247 (20,4%) 166 69% 75 31%   
71 - 80 129 (10,6%) 88 69% 40 31%
> 80 2 (0,2%) 2 100% 0 0%   
Disease stage stage II (high-risk) 205 (16.9%)  136 69% 61 31% 0.54
stage III 1007 (83.1%)  688 71% 278 29%   
Previous 
hypertension 
No 786 (64,9%) 545 72% 208 28% 0.12 
Yes 426 (35,1%) 279 68% 131 32%   
KRAS mutation* Positive 445 (36,7%) 296 68% 139 32% 0.04 
Negative 328 (27,1%) 226 70% 95 30%   
BRAF mutation* Mutation 78 (6,4%) 56 72% 22 28% 0.84 
Wildtype 994 (82,0%) 688 71% 285 29%   
MMR status* MSS 930 (76,7%) 631 69% 281 31% 0.01 
MSI 121 (10,0%) 97 80% 24 20%   
CEA (ng/L) <=5.0 1171 (96,6%) 799 71% 325 29% 0.08 
>5.0 28 (2,3%) 15 56% 12 44%   
Abbreviations: MMR status Mismatch Repair status, MSI Microsatellite instability, MSS Microsatellite stable, CEA Carcinoembryonic 
antigen 
* Data not available from all patients 
 



